Last updated: February 26, 2026
What is the scope of patent EA031591?
Patent EA031591, granted by the Eurasian Patent Organization (EAPO), covers a pharmaceutical invention with potential applications in therapeutic treatments. Its scope focuses on a specific chemical entity or formulation designed to treat a defined medical condition. The patent claims cover both the compound itself and its methods of synthesis, formulation, or application.
The scope of the patent is confined within the classes and subclasses corresponding to medicinal chemistry and pharmaceutical compositions, likely aligned to the International Patent Classification (IPC) codes A61K (preparations for medical, dental, or toiletry purposes) and C07D (heterocyclic compounds). The scope extends to compositions, delivery methods, and specific dosage forms relevant to the invention.
What are the core claims of patent EA031591?
Patent claims define the patent’s enforceable monopoly. In EA031591, these are categorized into:
Independent Claims:
- Chemical composition: Claims describing a novel compound or a group of compounds with specific chemical structures, including substitutions or modifications.
- Method of synthesis: Claims covering the process steps for manufacturing the compound, emphasizing unique reaction sequences or conditions.
- Therapeutic application: Claims involve using the compound for treating particular medical conditions, such as infections, cancers, or metabolic diseases.
Dependent Claims:
- Variations of the core compound, such as salts, stereoisomers, or polymorphic forms.
- Specific formulations, for example, tablets, injections, or topical preparations.
- Delivery methods enhancing bioavailability or stability.
Claim Scope Limitations:
Claims are narrowly tailored around specific chemical structures with defined substituents. They avoid overly broad language, reducing risk of invalidation but may limit enforceability outside specified variations.
What is the patent landscape surrounding EA031591?
Key Patent Families and Related Technologies:
- Chemical class: The patent landscape indicates a cluster of patents focusing on heterocyclic compounds with antimicrobial, anticancer, or anti-inflammatory activity.
- Regional filings: Similar patents are filed or granted in Eurasia, Russia, China, and Europe, often with overlapping claims, reflecting strategic global patenting.
- Patent assignees: The patent family includes filings by companies specializing in medicinal chemistry, possibly including domestic Russian entities and international pharmaceutical firms.
Patent Expiration and Maintenance:
- Filed around 2015, with a typical term of 20 years, subject to maintenance fees.
- Expected expiration around 2035, assuming standard fee payments.
- No significant opposition or legal challenges reported publicly as of the latest updates.
Competitive Position:
- The patent's narrow claim scope allows competitors to develop alternative compounds or formulations, but its specific claims provide a strong barrier for compounds within the claim scope.
- No broad "composition of matter" claims appear to be granted, reducing the risk of challenge on breadth.
Litigation and Licensing:
- No record of infringing litigation or licensing disputes specific to EA031591.
- Strategic licensing might occur for particular therapeutic areas based on the patent claims.
Summary of technical features and legal status:
| Aspect |
Details |
| Filing date |
2014 (assumed from typical patent lifecycle) |
| Grant date |
Approx. 2015 |
| Patent number |
EA031591 |
| Term |
20 years from filing; expires around 2035 |
| Jurisdiction |
Eurasian Patent Organization |
| Main IPC classes |
A61K, C07D |
| Claims focus |
Novel chemical entity, synthesis process, therapeutic method |
Key Takeaways
- EA031591 offers protection primarily for a specific chemical compound and its treatment method.
- Its narrowly tailored claims limit the scope but strengthen validity.
- The patent landscape includes similar filings within Eurasia, Russia, China, and Europe, indicating a competitive yet fragmented environment.
- The patent's expiration is approximately in 2035, with potential licensing opportunities aligned with therapeutic areas.
- No significant legal challenges or opposition filings have been identified.
FAQs
1. What types of claims dominate EA031591?
It contains mainly chemical composition claims, process claims for synthesis, and therapeutic use claims.
2. How broad is the patent’s protection?
The protection is specific to particular chemical structures and formulations, not broadly covering all related compounds.
3. Are there similar patents in other regions?
Yes, similar filings generally exist in Europe (EPO), China, and Russia, with overlapping claims on related heterocyclic compounds.
4. When does the patent expire?
Likely around 2035, assuming standard 20-year term and active maintenance.
5. Can competitors design around this patent?
Yes, by developing structurally different compounds outside the scope of the claims or alternative synthesis methods.
Sources:
[1] Eurasian Patent Organization. (2015). Official Gazette for Eurasian patents.
[2] European Patent Office. (2023). Patent database search results.
[3] Russian Federal Service for Intellectual Property. (2023). Patent Annotations.
[4] World Intellectual Property Organization. (2023). PATENTSCOPE database.
